A framework for fibrolamellar carcinoma research and clinical trials

Overview of attention for article published in Nature Reviews Gastroenterology & Hepatology, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 15 X users
facebook: 1 Facebook page

guideline: 2 clinical guideline sources

Readers on

mendeley: 56 Mendeley

So far, Altmetric has seen 18 X posts from 15 X users, with an upper bound of 97,072 followers.

@DrPatSoonShiong Dr. Soon-Shiong, can you help my 30yo wife who was diagnosed with a rare liver cancer (Fibrolamellar)? This disease affects younger adults and we seem so close to a cure. Boosting NK cells to fight the gene fusion could be a game change…

RT @Salihlab: Interesting review published in @NatRevGastroHep on the challenges in research and (immuno-)therapy of fibrolamellar carcinom…

Interesting review published in @NatRevGastroHep on the challenges in research and (immuno-)therapy of fibrolamellar carcinoma https://t.co/dlQChldcjQ #immunotherapy #FLC #livercancer

RT @NatRevGastroHep: MAY ISSUE | ROADMAP A framework for fibrolamellar carcinoma research and clinical trials https://t.co/Gb6Hopp6J6 #l…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 14 additional X posts.